Eugene B Cone1, Stewart S Dalton2, Megan Van Noord3, Elizabeth T Tracy4, Henry E Rice4, Jonathan C Routh5. 1. Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. 2. University of Florida College of Medicine, Gainesville, Florida. 3. Duke University Medical Library, Durham, North Carolina. 4. Division of Pediatric Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. 5. Division of Urologic Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina. Electronic address: Jonathan.Routh@duke.edu.
Abstract
PURPOSE: Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers. MATERIALS AND METHODS: We searched for English language studies from 1980 to 2015 performed in patients younger than 18 years with Wilms tumor and prognostic data. The protocol was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two reviewers abstracted data in duplicate using a standard evaluation form. We performed descriptive statistics, then calculated relative risks and 95% confidence intervals for markers appearing in multiple level II or III studies. RESULTS: A total of 40 studies were included examining 32 biomarkers in 7,381 patients with Wilms tumor. Studies had a median of 61 patients, 24 biomarker positive patients per series and a median followup of 68.4 months. Median percentages of patients with stages 1, 2, 3, 4 and 5 tumors were 28.5%, 26.4%, 24.5%, 14.1% and 1.7%, respectively, and 10.2% had anaplasia. The strongest negative prognostic association was loss of heterozygosity at 11p15, with a risk of recurrence of 5.00, although loss of heterozygosity at 1p and gain of function at 1q were also strongly linked to increased recurrence (2.93 and 2.86, respectively). CONCLUSIONS: Several tumor markers are associated with an increased risk of recurrence or a decreased risk of overall survival in patients with Wilms tumor. These data suggest targets for development of diagnostic tests and potential therapies.
PURPOSE:Wilms tumor is the most common childhood renal malignancy and the fourth most common childhood cancer. Many biomarkers have been studied but there has been no comprehensive summary. We systematically reviewed the literature on biomarkers in Wilms tumor to quantify the prognostic implications of the presence of individual tumor markers. MATERIALS AND METHODS: We searched for English language studies from 1980 to 2015 performed in patients younger than 18 years with Wilms tumor and prognostic data. The protocol was conducted per PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines. Two reviewers abstracted data in duplicate using a standard evaluation form. We performed descriptive statistics, then calculated relative risks and 95% confidence intervals for markers appearing in multiple level II or III studies. RESULTS: A total of 40 studies were included examining 32 biomarkers in 7,381 patients with Wilms tumor. Studies had a median of 61 patients, 24 biomarker positive patients per series and a median followup of 68.4 months. Median percentages of patients with stages 1, 2, 3, 4 and 5 tumors were 28.5%, 26.4%, 24.5%, 14.1% and 1.7%, respectively, and 10.2% had anaplasia. The strongest negative prognostic association was loss of heterozygosity at 11p15, with a risk of recurrence of 5.00, although loss of heterozygosity at 1p and gain of function at 1q were also strongly linked to increased recurrence (2.93 and 2.86, respectively). CONCLUSIONS: Several tumor markers are associated with an increased risk of recurrence or a decreased risk of overall survival in patients with Wilms tumor. These data suggest targets for development of diagnostic tests and potential therapies.
Authors: M A Ghanem; T H Van Der Kwast; J C Den Hollander; M K Sudaryo; R B Mathoera; M M Van den Heuvel; M A Noordzij; R J Nijman; G J van Steenbrugge Journal: Cancer Date: 2001-12-15 Impact factor: 6.860
Authors: M J Coppes; J de Kraker; P J van Dijken; H J Perry; J F Delemarre; M F Tournade; J Lemerle; P A Voûte Journal: J Clin Oncol Date: 1989-03 Impact factor: 44.544
Authors: J S Dome; S Chung; T Bergemann; C B Umbricht; M Saji; L A Carey; P E Grundy; E J Perlman; N E Breslow; S Sukumar Journal: Cancer Res Date: 1999-09-01 Impact factor: 12.701
Authors: R Houston Thompson; Susan M Kuntz; Bradley C Leibovich; Haidong Dong; Christine M Lohse; W Scott Webster; Shomik Sengupta; Igor Frank; Alexander S Parker; Horst Zincke; Michael L Blute; Thomas J Sebo; John C Cheville; Eugene D Kwon Journal: Cancer Res Date: 2006-04-01 Impact factor: 12.701
Authors: Mazen A Ghanem; Gert J Van Steenbrugge; Theo H Van Der Kwast; Mondastri K Sudaryo; Marinus A Noordzij; Rien J M Nijman Journal: J Urol Date: 2002-08 Impact factor: 7.450
Authors: M A Ghanem; G J van Steenbrugge; M K Sudaryo; R B Mathoera; J M Nijman; Th H van der Kwast Journal: J Clin Pathol Date: 2003-02 Impact factor: 3.411
Authors: M A Ghanem; T H Van der Kwast; J C Den Hollander; M K Sudaryo; M M Van den Heuvel; M A Noordzij; R J Nijman; E H Soliman; G J van Steenbrugge Journal: Br J Cancer Date: 2001-11-16 Impact factor: 7.640
Authors: Beatriz de Camargo; Sheila Coelho Soares Lima; Bruna M de Sá Pereira; Rafaela Montalvão-de-Azevedo; Paulo Antônio Faria; Neimar de Paula Silva; Pedro Nicolau-Neto; Mariana Maschietto Journal: Clin Epigenetics Date: 2017-12-12 Impact factor: 6.551
Authors: João Victor da Silva Guerra; Bruna Maria de Sá Pereira; Jéssica Gonçalves Vieira da Cruz; Nicole de Miranda Scherer; Carolina Furtado; Rafaela Montalvão de Azevedo; Paulo Sergio Lopes de Oliveira; Paulo Faria; Mariana Boroni; Beatriz de Camargo; Mariana Maschietto Journal: Cells Date: 2019-08-17 Impact factor: 6.600
Authors: Jun Eun Park; O Kyu Noh; Yonghee Lee; Hyoung Soo Choi; Jung Woo Han; Seung Min Hahn; Chuhl Joo Lyu; Ji Won Lee; Keon Hee Yoo; Hong Hoe Koo; Seon-Yong Jeong; Ki Woong Sung Journal: Cancer Res Treat Date: 2019-09-10 Impact factor: 4.679